New Mechanisms in Glucose Control

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP–1 agonists) and DPP–4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus. This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.   New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

1 Epidemiology and pathogenesis of type 2 diabetes. 2 Overview of current diabetes management. 3 The incretin system. 4 The incretin mimetics. 5 The dipeptidyl peptidase 4 inhibitors. 6 Sodium–glucose cotransporter–2 inhibitors. 7 Pipeline diabetes therapies. 8 Bariatric surgery for the treatment of type 2 diabetes. 9 Organisation of diabetes care. Index.

Anthony Barnett , Diabetes Centre, Birmingham Heartlands Hospital, Birmingham, UK Jenny Grice , Medical Writer, France

"In general, this text provides a good account and succinct account of the advantages and disadvantages of the growing number of treatment options for a widely prevalent condition. It should be very helpful to those with the responsibility of providing immediate care to those with diabetes mellitus." (Applied Physiology, Nutrition & Metabolism, 6 August 2011)